El Dorado Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 2.27 M
as on 17-07-2024
- Company Age 21 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.10 Cr
as on 17-07-2024
- Revenue 107.87%
(FY 2023)
- Profit 30.35%
(FY 2023)
- Ebitda -3453.30%
(FY 2023)
- Net Worth 1.10%
(FY 2023)
- Total Assets -67.99%
(FY 2023)
About El Dorado Biotech
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.27 M.
The company has closed loans amounting to ₹1.10 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sandeep Thakur and Ajay Patel serve as directors at the Company.
- CIN/LLPIN
U24119GJ2003PTC042521
- Company No.
042521
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jun 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at El Dorado Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Thakur  | Director | 16-Feb-2023 | Current |
| Ajay Patel | Director | 19-Jun-2003 | Current |
Financial Performance and Corporate Structure Insights of El Dorado Biotech.
El Dorado Biotech Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 107.87% increase. The company also saw a substantial improvement in profitability, with a 30.35% increase in profit. The company's net worth moved up by a moderate rise of 1.1%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of El Dorado Biotech?
In 2023, El Dorado Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Fortune Gilts Private LimitedActive 21 years 9 months
Sandeep Thakur and Ajay Patel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 07 Nov 2014 | ₹3.80 M | Satisfied |
Axis Bank Limited Creation Date: 15 Oct 2014 | ₹7.20 M | Satisfied |
How Many Employees Work at El Dorado Biotech?
El Dorado Biotech has a workforce of 3 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of El Dorado Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped El Dorado Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
